Evidence map›Paper›PMID 42351690›Full record

ArticleBiomedicines2026

ZIP7 Drives Glycolytic Reprogramming and Lactate-Mediated Immune Remodeling in Lung Adenocarcinoma Through GSK3β-NRF2 Signaling.

Zhihua Tang, Yueli Shi, Xinyuan Jiang, Sujing Jiang, Nueraili Maihemuti, Jie Zhang, Bufu Tang, Zhiyong Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhihua TangInstitute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Yueli ShiZhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
Xinyuan JiangThe Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
Sujing JiangThe Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
Nueraili MaihemutiThe Fourth Affiliated Hospital of School of Medicine, International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu 322000, China.
Jie ZhangSir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.ORCID 0000-0002-9957-077X
Bufu TangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Zhiyong XuInstitute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

Funding

National Natural Science Foundation of China 32300753National Natural Science Foundation of China 82203608
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

anti-PD-1 therapyglycolysislung adenocarcinomaNRF2tumor-associated macrophagesZIP7

Identifiers

PMID42351690
PMCPMC13296730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.